Skip to content

Vertex Pharmaceuticals

US · VRTX #155 by market cap Listed 1970
515.02 -5.64 -1.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 32 in the most recent period (2026/Q3).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
96.94% +0.00pp
Institutions
2,129 +32
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund86.48%
Public Company3.21%
Hedge Fund1.90%
Government Pension Fund1.87%
Private Company1.36%
Sovereign Wealth Fund1.26%
Insurance Company0.31%
Individual/Insider0.20%
Family Office/Trust0.18%
Other3.22%

Top holders as of 2026-06-30

Capital Research 20.05% · 50.81M sh
BlackRock 9.51% · 24.11M sh
Vanguard Capital Management, LLC 7.10% · 18.01M sh
State Street Global Advisors 4.68% · 11.87M sh
Invesco Capital Management LLC 2.93% · 7.43M sh
Other 55.72%
Geode Capital Management, LLC 2.40% · 6.08M sh
J.P. Morgan Asset Management, Inc. 2.12% · 5.38M sh
Vanguard Portfolio Management, LLC 1.92% · 4.88M sh
Loomis, Sayles & Company L.P. 1.55% · 3.92M sh
UBS Asset Management 1.50% · 3.80M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 28 buys · 22 sells

NameRoleStake
Amit Sachdev Executive VP & Chief Patient and External Affairs Officer 0.03%
Stuart Arbuckle Former Chief Operating Officer 0.03%
Ourania Tatsis Executive VP & Chief Product Affairs Officer 0.02%
Reshma Kewalramani Chief Executive Officer 0.02%
Bruce Sachs Lead Independent Director 0.02%
Jeffrey Leiden Executive Chairperson 0.01%
David Altshuler Former Officer 0.01%
Charles Wagner Chief Operating Officer 0.01%
Joy Liu EVP, Chief Legal Officer & Corporate Secretary 0.01%
Edward Atkinson EVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Charles Wagner Chief Operating Officer Intent to Sell (Form 144) -15,286 $547.87
2026-11-05 Reshma Kewalramani Chief Executive Officer Open Market Disposition -11,866 $531.53
2026-10-19 Daniel Brennan Independent Director Other Acquisition +795 $503.47
2026-10-14 Bruce Sachs Lead Independent Director Other Derivative Acquisition +92 --
2026-10-14 Alan Garber Independent Director Other Derivative Acquisition +29 --
2026-09-07 Jasper van Grunsven Executive VP & Chief Pain & New Product Planning Officer Other Acquisition +8,682 --
2026-08-27 Kristen Ambrose Chief Accounting Officer Other Acquisition +5,000 --
2026-08-26 Bruce Sachs Lead Independent Director Other Disposition -6,000 --
2026-07-20 Amit Sachdev Executive VP & Chief Patient and External Affairs Officer Other Acquisition +8,251 --
2026-07-20 Ourania Tatsis Executive VP & Chief Product Affairs Officer Other Acquisition +8,251 --
2026-07-14 Bruce Sachs Lead Independent Director Other Derivative Acquisition +99 --
2026-07-14 Alan Garber Independent Director Other Derivative Acquisition +31 --
2026-07-01 Ourania Tatsis Executive VP & Chief Product Affairs Officer Automatic Disposition -1,500 $524.99
2026-07-01 Duncan McKechnie Executive Vice President Automatic Disposition -1,541 $519.00
2026-06-30 Joy Liu EVP, Chief Legal Officer & Corporate Secretary Automatic Disposition -828 $502.71
2026-06-25 Carmen Bozic Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer Automatic Disposition -596 $482.50
2026-06-17 Carmen Bozic Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer Automatic Disposition -1,020 $462.17
2026-06-14 Carmen Bozic Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer Automatic Disposition -4,062 $450.00
2026-06-04 Carmen Bozic Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer Automatic Disposition -1,745 $450.00
2026-05-31 Joy Liu EVP, Chief Legal Officer & Corporate Secretary Automatic Disposition -828 $439.91

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.

Vertex Pharmaceuticals discussion 0 comments

Add a comment